U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Midgut Neuroendocrine Tumor

MedGen UID:
1715146
•Concept ID:
C5238467
•
Neoplastic Process

Definition

A midgut neuroendocrine tumor that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Midgut Neuroendocrine Tumor

Professional guidelines

PubMed

Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y, Ikeda M, Hijioka S, Matsumoto S, Ito T, Aoki T, Furuse J
Invest New Drugs 2023 Dec;41(6):777-786. Epub 2023 Oct 19 doi: 10.1007/s10637-023-01399-8. PMID: 37856005
Management of neuroendocrine tumors.
Chung C
Am J Health Syst Pharm 2016 Nov 1;73(21):1729-1744. doi: 10.2146/ajhp150373. PMID: 27769969
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G
Dig Liver Dis 2012 Feb;44(2):95-105. Epub 2011 Oct 7 doi: 10.1016/j.dld.2011.08.022. PMID: 21983252

Recent clinical studies

Etiology

Safety and response after peptide receptor radionuclide therapy with (177) Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial.
Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, Kobayashi N, Utsunomiya D, Hata M, Ichikawa Y, Tanabe M, Hosono M, Kinuya S
J Hepatobiliary Pancreat Sci 2022 Apr;29(4):487-499. Epub 2021 Dec 27 doi: 10.1002/jhbp.1101. PMID: 34907652
Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.
Polcz M, Schlegel C, Edwards GC, Wang F, Tan M, Kiernan C, Solórzano CC, Idrees K, Parikh A, Bailey CE
Ann Surg Oncol 2020 Aug;27(8):2795-2803. Epub 2020 May 19 doi: 10.1245/s10434-020-08602-7. PMID: 32430752Free PMC Article
Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM
J Gastrointest Surg 2019 May;23(5):1044-1054. Epub 2019 Jan 22 doi: 10.1007/s11605-018-04094-9. PMID: 30671800
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
Guo J, Zhang Q, Bi X, Zhou J, Li Z, Huang Z, Zhang Y, Li M, Chen X, Hu X, Yihebali C, Liang J, Liu J, Zhao J, Cai J, Zhao H
Oncotarget 2017 Mar 7;8(10):17396-17405. doi: 10.18632/oncotarget.14156. PMID: 28030811Free PMC Article
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G
Dig Liver Dis 2012 Feb;44(2):95-105. Epub 2011 Oct 7 doi: 10.1016/j.dld.2011.08.022. PMID: 21983252

Diagnosis

Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France.
Leeuwenkamp O, Smith-Palmer J, Ortiz R, Werner A, Valentine W, Blachier M, Walter T
J Med Econ 2020 Dec;23(12):1534-1541. Epub 2020 Oct 16 doi: 10.1080/13696998.2020.1830286. PMID: 32990484
Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.
Polcz M, Schlegel C, Edwards GC, Wang F, Tan M, Kiernan C, Solórzano CC, Idrees K, Parikh A, Bailey CE
Ann Surg Oncol 2020 Aug;27(8):2795-2803. Epub 2020 May 19 doi: 10.1245/s10434-020-08602-7. PMID: 32430752Free PMC Article
Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM
J Gastrointest Surg 2019 May;23(5):1044-1054. Epub 2019 Jan 22 doi: 10.1007/s11605-018-04094-9. PMID: 30671800
Management of neuroendocrine tumors.
Chung C
Am J Health Syst Pharm 2016 Nov 1;73(21):1729-1744. doi: 10.2146/ajhp150373. PMID: 27769969
New treatment strategies in advanced neuroendocrine tumours.
Walter T, Brixi-Benmansour H, Lombard-Bohas C, Cadiot G
Dig Liver Dis 2012 Feb;44(2):95-105. Epub 2011 Oct 7 doi: 10.1016/j.dld.2011.08.022. PMID: 21983252

Therapy

Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y, Ikeda M, Hijioka S, Matsumoto S, Ito T, Aoki T, Furuse J
Invest New Drugs 2023 Dec;41(6):777-786. Epub 2023 Oct 19 doi: 10.1007/s10637-023-01399-8. PMID: 37856005
Safety and response after peptide receptor radionuclide therapy with (177) Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial.
Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, Kobayashi N, Utsunomiya D, Hata M, Ichikawa Y, Tanabe M, Hosono M, Kinuya S
J Hepatobiliary Pancreat Sci 2022 Apr;29(4):487-499. Epub 2021 Dec 27 doi: 10.1002/jhbp.1101. PMID: 34907652
Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM
J Gastrointest Surg 2019 May;23(5):1044-1054. Epub 2019 Jan 22 doi: 10.1007/s11605-018-04094-9. PMID: 30671800
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
Guo J, Zhang Q, Bi X, Zhou J, Li Z, Huang Z, Zhang Y, Li M, Chen X, Hu X, Yihebali C, Liang J, Liu J, Zhao J, Cai J, Zhao H
Oncotarget 2017 Mar 7;8(10):17396-17405. doi: 10.18632/oncotarget.14156. PMID: 28030811Free PMC Article
Management of neuroendocrine tumors.
Chung C
Am J Health Syst Pharm 2016 Nov 1;73(21):1729-1744. doi: 10.2146/ajhp150373. PMID: 27769969

Prognosis

Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y, Ikeda M, Hijioka S, Matsumoto S, Ito T, Aoki T, Furuse J
Invest New Drugs 2023 Dec;41(6):777-786. Epub 2023 Oct 19 doi: 10.1007/s10637-023-01399-8. PMID: 37856005
Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM
J Gastrointest Surg 2019 May;23(5):1044-1054. Epub 2019 Jan 22 doi: 10.1007/s11605-018-04094-9. PMID: 30671800
Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N
Invest New Drugs 2019 Jun;37(3):573-578. Epub 2018 Sep 28 doi: 10.1007/s10637-018-0669-7. PMID: 30267338
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
Guo J, Zhang Q, Bi X, Zhou J, Li Z, Huang Z, Zhang Y, Li M, Chen X, Hu X, Yihebali C, Liang J, Liu J, Zhao J, Cai J, Zhao H
Oncotarget 2017 Mar 7;8(10):17396-17405. doi: 10.18632/oncotarget.14156. PMID: 28030811Free PMC Article
Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases.
Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M
Br J Surg 2012 Nov;99(11):1480-6. Epub 2012 Sep 13 doi: 10.1002/bjs.8842. PMID: 22972490

Clinical prediction guides

Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y, Ikeda M, Hijioka S, Matsumoto S, Ito T, Aoki T, Furuse J
Invest New Drugs 2023 Dec;41(6):777-786. Epub 2023 Oct 19 doi: 10.1007/s10637-023-01399-8. PMID: 37856005
Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N
Invest New Drugs 2019 Jun;37(3):573-578. Epub 2018 Sep 28 doi: 10.1007/s10637-018-0669-7. PMID: 30267338
Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S
Eur J Nucl Med Mol Imaging 2015 Jul;42(8):1238-46. Epub 2015 Mar 26 doi: 10.1007/s00259-015-3041-6. PMID: 25808630
Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors.
Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK
J Clin Oncol 2013 Feb 1;31(4):420-5. Epub 2012 Dec 17 doi: 10.1200/JCO.2012.44.5924. PMID: 23248248

Recent systematic reviews

Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
Tsilimigras DI, Ntanasis-Stathopoulos I, Kostakis ID, Moris D, Schizas D, Cloyd JM, Pawlik TM
J Gastrointest Surg 2019 May;23(5):1044-1054. Epub 2019 Jan 22 doi: 10.1007/s11605-018-04094-9. PMID: 30671800
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M
Health Technol Assess 2018 Sep;22(49):1-326. doi: 10.3310/hta22490. PMID: 30209002Free PMC Article
Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases.
Guo J, Zhang Q, Bi X, Zhou J, Li Z, Huang Z, Zhang Y, Li M, Chen X, Hu X, Yihebali C, Liang J, Liu J, Zhao J, Cai J, Zhao H
Oncotarget 2017 Mar 7;8(10):17396-17405. doi: 10.18632/oncotarget.14156. PMID: 28030811Free PMC Article
Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases.
Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M
Br J Surg 2012 Nov;99(11):1480-6. Epub 2012 Sep 13 doi: 10.1002/bjs.8842. PMID: 22972490

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...